Carolinas HealthCare System

Research and Clinical Trials

HIV 

Brief Description Principal Investigator
The purpose of this study is to evaluate the experimental drug elvitegravir which is one of a new class of anti-HIV medications called integrase inhibitors. The study will attempt to determine if elvitegravir is safe and effective when given in combination with the background regimen (the other antiviral medications that a patient may currently be taking or will take to participate in the study), in subjects who are failing their current regimen of HIV medications. Johnson, Marc 
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) active against HIV-1 with demonstrated potency in treatment-experienced patients and potent short-term activity in treatment naïve patients reducing plasma HIV RNA. To date, etravirine has not been evaluated as part of combination antiretroviral therapy for naive patients initiating treatment for HIV infection. Johnson, Marc 
The purpose of this study is to see if the combination pill FTC/RPV/TDF is safe and effective in reducing levels of HIV-1 in the blood of subjects who are treatment-naïve (those who have not received any antiretroviral medication).The safety and effectiveness of FTC/RPV/TDF will be compared with that of Atripla®, a combination medication containing efavirenz, FTC, and TDF. Atripla® has been approved by the FDA for the treatment of HIV. An approved dose of Atripla® is being used in this study. Johnson, Marc 
This trial is looking at the safety, tolerability and effectiveness of a medication named cobisitat in HIV postitive individuals. Both naïve (never been on therapy) and treatment experienced patients are being considered. This trial will be looking at the effectiveness of the combination of Darunavir with cobisistat with an investigator defined backbone. The duration of this trial is at least 48 weeks or approximately one year. Johnson, Marc 
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of the combination of etravirine 400mg with darunavir/ritonavir 800/100mg, all given once a day. In addition, this study will compare changes in cholesterol and blood sugar, along with changes in body fat, bone density, and markers of inflammation and immune function from Baseline (Day 1) to Week 48. Finally, the study will also assess the levels of these drugs in the body. Johnson, Marc 
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem.

The purpose of this study is to see if the investigational compound of elvitegravir/emtricitabine/tenofovir/cobicistat (EVG/FTC/TDF/GS-9350) is safe and effective in reducing levels of HIV in the blood of subjects who are treatment-naïve (those who have not received any antiretroviral medication).
Johnson, Marc 
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem.

The purpose of this study is to see if the investigational compound of elvitegravir/emtricitabine/tenofovir/cobicistat (EVG/FTC/TDF/GS-9350) is safe and effective in reducing levels of HIV in the blood of subjects who are treatment-naïve (those who have not received any antiretroviral medication).
Johnson, Marc 
With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem.

The purpose of this study is to evaluate the safety of a new medication (GSK1349572) in HIV infected individuals who have never taken antiretroviral medications before. This study is also comparing the efficacy of GSK1349572 + epzicom to Atripla which is currently one of the medications used for HIV therapy.
Johnson, Marc 
To determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whome the HIV-1 virus is currently suppressed. Johnson, Marc 
The purpose of this study is to determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed Johnson, Marc 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.